| Atrial Fibrillation
Sotylize vs Pradaxa
Side-by-side clinical, coverage, and cost comparison for atrial fibrillation.Deep comparison between: Sotylize vs Pradaxa with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsPradaxa has a higher rate of injection site reactions vs Sotylize based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Pradaxa but not Sotylize, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Sotylize
Pradaxa
At A Glance
Oral
Twice daily
Class II/III antiarrhythmic
Oral
Twice daily
Direct thrombin inhibitor
Indications
- Ventricular arrhythmia
- Atrial Fibrillation
- Atrial Flutter
- Atrial Fibrillation
- Deep Vein Thrombosis
- Pulmonary Embolism
Dosing
Ventricular arrhythmia Initial 80 mg orally twice daily; increase by 80 mg/day every 3 days to a maximum 320 mg/day, with therapeutic response typically at 160-320 mg/day in two or three divided doses.
Atrial Fibrillation, Atrial Flutter Initial 80 mg orally twice daily; increase by 80 mg/day every 3 days provided QTc <500 msec; most patients respond at 120 mg twice daily.
Atrial Fibrillation CrCl > 30 mL/min: 150 mg orally twice daily; CrCl 15-30 mL/min: 75 mg orally twice daily; reduce to 75 mg twice daily if CrCl 30-50 mL/min with concomitant dronedarone or systemic ketoconazole.
Deep Vein Thrombosis, Pulmonary Embolism Treatment: 150 mg orally twice daily after 5-10 days of parenteral anticoagulation (CrCl > 30 mL/min); recurrence reduction: 150 mg orally twice daily after previous treatment (CrCl > 30 mL/min).
Prophylaxis of DVT and PE Following Hip Replacement Surgery 110 mg orally on day 1 (1-4 hours after surgery and after hemostasis), then 220 mg once daily for 28-35 days (CrCl > 30 mL/min).
Pediatric VTE Weight-based dosage orally twice daily after at least 5 days of parenteral anticoagulant (ages 8 to <18 years); adjust dose per actual weight as treatment progresses.
Contraindications
- Baseline QT interval >450 msec
- Sinus bradycardia, sick sinus syndrome, or second and third degree AV block without a functioning pacemaker
- Congenital or acquired long QT syndromes
- Cardiogenic shock or decompensated heart failure
- Hypokalemia
- Bronchial asthma or related bronchospastic conditions
- Hypersensitivity to sotalol
- Active pathological bleeding
- History of serious hypersensitivity reaction to dabigatran, dabigatran etexilate, or any excipient (e.g., anaphylactic reaction or anaphylactic shock)
- Mechanical prosthetic heart valve
Adverse Reactions
Most common (>=2%) Fatigue, bradycardia, dyspnea, proarrhythmia, asthenia, dizziness.
Serious Sustained ventricular tachycardia/ventricular fibrillation, Torsade de Pointes.
Postmarketing Emotional liability, slightly clouded sensorium, incoordination, vertigo, paralysis, thrombocytopenia, eosinophilia, leukopenia, photosensitivity reaction, fever, pulmonary edema, hyperlipidemia, myalgia, pruritus, alopecia.
Most common Bleeding events (major and minor), gastrointestinal adverse reactions (dyspepsia, nausea, vomiting, upper abdominal pain, diarrhea, gastritis-like symptoms)
Serious Intracranial hemorrhage, major gastrointestinal hemorrhage, anaphylactic reaction, anaphylactic shock
Postmarketing Agranulocytosis, neutropenia, thrombocytopenia, esophageal ulcer, angioedema, anticoagulant-related nephropathy, alopecia
Pharmacology
Sotalol is a non-cardioselective beta-adrenoreceptor blocker (Vaughan Williams Class II) with cardiac action potential duration prolongation (Class III) antiarrhythmic properties; it slows heart rate, decreases AV nodal conduction, and increases refractory periods of atrial and ventricular muscle and conduction tissue.
Dabigatran and its acyl glucuronides are competitive, direct thrombin inhibitors that prevent thrombus formation by blocking thrombin-mediated conversion of fibrinogen to fibrin and inhibiting thrombin-induced platelet aggregation, acting on both free and clot-bound thrombin.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Sotylize
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (0/12) · Qty limit (0/12)
Pradaxa
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Sotylize
- Covered on 4 commercial plans
- PA (3/8) · Step Therapy (0/8) · Qty limit (0/8)
Pradaxa
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (1/8)
Humana
Sotylize
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Pradaxa
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availablePAF Co-Pay Relief: Cardiac Arrhythmias
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Pradaxa.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SotylizeView full Sotylize profile
PradaxaView full Pradaxa profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.